In 2005, the first GLP-1 got FDA approval to manage type 2 diabetes due to its ability to keep blood sugar stable, with others soon following
[DOI] [PMC free article] [PubMed] [Google Scholar] 21
(Tirzepatide, sold as Mounjaro for diabetes and newly approved as Zepbound for weight loss, targets both GLP-1 and GIP.) Glucagon: a hormone that normally raises blood sugar, but when cleverly harnessed can increase energy expenditure and fat burning
A smores-inspired elevated Greek yogurt that tastes more like a pudding
The most commonly reported adverse effects in the Phase 2 trial included: Nausea the most prevalent side effect, particularly during dose escalation Vomiting Diarrhoea Constipation Decreased appetite (which, whilst contributing to weight loss, can be uncomfortable) Eructation (belching) Injection-site reactions (such as redness, bruising, or discomfort at the injection site) These effects are typically mild to moderate in severity and tend to be most pronounced during the first few weeks of treatment or following each dose increase
How retatrutide and Mounjaro work differently Both medications work by mimicking hormones that influence our hunger and appetite, but retatrutide mimics one more hormone than Mounjaro
